The ubiquitous sports supplement creatine, a staple for athletes seeking to enhance strength and muscle performance, is now under scrutiny for a far more profound potential: alleviating symptoms of depression. A recent systematic review published in the esteemed journal Brain Medicine has delved into the burgeoning scientific interest surrounding creatine’s capacity to support the brain’s energy needs and, consequently, offer relief to individuals battling mood disorders. While the findings offer a glimmer of cautious optimism, they underscore the complex and often elusive nature of mental health research, presenting a nuanced picture rather than a definitive answer.
The Groundbreaking Review: Synthesizing Existing Evidence
The comprehensive review, spearheaded by Bassam Jeryous Fares of the University of Ottawa, did not involve new experimental trials. Instead, it meticulously synthesized the findings from existing clinical research, aiming to consolidate the current understanding of creatine’s role in depression treatment. The research team sifted through the available literature, ultimately identifying six published reports that encompassed five distinct randomized controlled trials. These trials adhered to the gold standard of scientific inquiry, employing a placebo-controlled design where participants were unaware of whether they were receiving creatine or an inert substance. This rigorous methodology is crucial for minimizing bias and ensuring that any observed effects can be more confidently attributed to the intervention itself.
The geographical spread of these foundational studies is notable, with research originating from South Korea, the United States, Brazil, Israel, and India. This global distribution suggests an international scientific community converging on this intriguing hypothesis. Collectively, these five trials involved 238 participants at their inception. Of these, 126 individuals were allocated to receive creatine, while 112 were assigned to the placebo group. The demographic profile of the participants revealed an average age of 36 years, with a notable overrepresentation of women. Indeed, two of the enrolled studies exclusively recruited female participants, a factor that may hold significant implications for future research and the generalizability of findings.
The scope of the reviewed trials varied, with four focusing specifically on individuals diagnosed with major depressive disorder (MDD). The fifth trial, however, included participants with bipolar disorder who were experiencing a depressive episode. This distinction is important, as the underlying neurobiology and treatment responses in MDD and bipolar depression can differ. The heterogeneity in study designs and methodologies prevented the researchers from conducting a unified statistical analysis. Consequently, the review adopted an individual-case evaluation approach, meticulously examining the outcomes of each study on its own merits.
A Divided Landscape: Mixed Results Emerge
The systematic review painted a divided picture regarding creatine’s efficacy in alleviating depressive symptoms. Two of the five trials, both of which involved women diagnosed with major depressive disorder, reported positive and statistically significant benefits. In one of these studies, participants who received five grams of creatine daily in conjunction with the antidepressant escitalopram demonstrated markedly greater reductions in depressive symptoms after an eight-week period compared to their counterparts who received escitalopram with a placebo. This improvement was deemed substantial by conventional statistical metrics, indicated by a large Cohen’s d value of 1.13 on the Hamilton Depression Rating Scale (HAM-D). Furthermore, a higher proportion of participants in the creatine group achieved remission of their depressive symptoms.
In another promising study, creatine was administered alongside cognitive behavioral therapy (CBT), a widely recognized psychotherapeutic approach for depression. Here too, participants receiving creatine exhibited a more significant decrease in depression symptoms, as measured by a standard assessment tool, compared to those undergoing CBT with a placebo. These findings suggest that creatine might act synergistically with existing therapeutic interventions, potentially amplifying their positive effects.
However, the remaining three trials presented a starkly contrasting outcome, reporting no discernible benefit from creatine supplementation. One study explored the impact of both five and ten grams of creatine per day in individuals whose depression had proven resistant to conventional medication. Despite these varied dosages, no improvement in symptoms was observed. Similarly, another trial involving adolescent girls failed to find any advantage of creatine over placebo, even when different doses were tested. A third study, which focused on individuals with bipolar disorder experiencing depressive episodes, also concluded that creatine did not lead to any significant improvement in their condition.
Beyond the efficacy data, a critical safety concern was highlighted within the review. Two participants with bipolar disorder who were administered creatine experienced episodes of hypomania or mania. This finding is particularly concerning, as it suggests that creatine might interact with the underlying neurochemistry of individuals with bipolar disorder in a way that could trigger manic or hypomanic states. This raises a significant red flag for the potential differential effects of creatine based on an individual’s specific mental health condition.
The Neurological Rationale: Brain Energy and Neurotransmitter Pathways
The scientific rationale underpinning the investigation into creatine’s potential antidepressant properties is rooted in the brain’s exceptionally high energy demands. While creatine is predominantly recognized for its role in rapidly regenerating adenosine triphosphate (ATP)—the primary energy currency of cells—within muscle tissue, the brain also relies heavily on this ATP-generating system. Previous research has identified alterations in brain creatine metabolism among individuals with mood disorders, prompting scientists to hypothesize that disruptions in cellular energy production might contribute to the pathophysiology of depression.
The brain, a metabolically demanding organ, requires a constant and robust supply of energy to function optimally. Creatine plays a crucial role in buffering cellular energy levels by facilitating the rapid transfer of phosphate groups to ADP, thereby replenishing ATP stores. In conditions where cellular energy production is compromised, such as potentially in depression, creatine supplementation could theoretically help restore this energetic balance.
Furthermore, emerging research suggests that creatine might also influence the activity of key neurotransmitters involved in mood regulation, namely dopamine and serotonin. These neurotransmitters are well-established targets for many antidepressant medications, and dysregulation in their pathways is strongly implicated in the development and maintenance of depressive disorders. While the precise mechanisms by which creatine might influence these neurotransmitter systems are still being elucidated, preliminary findings suggest a potential modulatory effect.
Despite these compelling theoretical underpinnings, the authors of the review strongly emphasize that these connections remain largely speculative. The existing studies, while provocative, primarily demonstrate correlations rather than definitive causal links. They highlight that altered creatine metabolism is observed in depression but do not definitively prove that such alterations are a direct cause of the disorder. Depression is a complex, multifactorial illness influenced by a confluence of genetic, environmental, and biological factors, and it is unlikely that a single supplement could offer a panacea.
Bassam Jeryous Fares, the lead author of the review, articulated this sentiment with clarity: "The signal is interesting, but it is not a verdict. Two trials pointed one way and three pointed another. That is not the kind of evidence on which you change clinical practice. It is the kind that tells you the question is worth further exploration." This statement aptly captures the current scientific standing of creatine as a potential depression treatment—a promising avenue requiring further rigorous investigation.
Nicholas Fabiano, the corresponding author and a psychiatry resident at the University of Ottawa, echoed this call for prudence. He noted, "Creatine appears to be a safe intervention. The adverse events we found were limited to mild gastrointestinal discomfort. We cannot yet reliably say that creatine helps with depressive symptoms or if the findings are generalizable to everyone." This balanced perspective acknowledges the safety profile while underscoring the current limitations in establishing efficacy and broad applicability.
The Road Ahead: The Imperative for Larger, More Robust Studies
The researchers are unequivocal in their assertion that the current body of evidence is insufficient to recommend the routine use of creatine for the management of depression. The clinical trials reviewed were characterized by several limitations that temper the enthusiasm generated by the positive findings. These limitations include relatively small sample sizes, a disproportionate representation of women compared to men, and variations in study quality.
A critical aspect of scientific rigor is the assessment of bias. In the reviewed studies, only two were judged to have a low risk of bias, a measure of how well the study design and execution minimize the potential for systematic errors. The remaining three studies raised some concerns, primarily related to the methods used for participant assignment to treatment groups and the handling of missing data. Such concerns can cast doubt on the reliability and validity of the reported outcomes. Consequently, the findings from these studies cannot be broadly generalized to the wider population of individuals experiencing depression.
To address these shortcomings and definitively ascertain creatine’s therapeutic potential, the review authors advocate for larger, longer-term clinical trials. Extending the duration of these trials beyond the typical eight-week period is crucial for understanding the sustained effects of creatine and for observing potential long-term benefits or side effects. Furthermore, researchers recommend exploring creatine’s efficacy in conjunction with other established interventions, such as exercise, which has well-documented antidepressant properties. Investigating the impact of different dosages is also a key recommendation, although the review acknowledges that higher doses do not necessarily equate to greater benefits.
Intriguingly, animal studies may offer additional insights into the sex-specific effects of creatine. Experiments have indicated that creatine can influence depression-like behaviors differently in male and female rodents. This finding could provide a biological explanation for why the human studies that yielded the most robust positive results predominantly involved women. Understanding these sex differences could be pivotal in designing future trials and tailoring treatment approaches.
Conclusion: An Intriguing Possibility Awaiting Validation
For the present, creatine remains an intriguing possibility rather than a validated treatment for depression. The supplement, long associated with the tangible pursuit of physical prowess, is now capturing the attention of scientists engaged in the complex and vital search for novel strategies to combat mental illness. The journey from popular sports supplement to a potential therapeutic agent for depression is a testament to the ever-evolving landscape of scientific discovery, where established compounds are continuously re-examined for unexpected applications.
The peer-reviewed research article, titled "Creatine as a treatment for depression," was published in Brain Medicine and has been available through Open Access since June 30, 2026. This accessibility allows for broader engagement with the scientific community and facilitates further research and discussion on this promising yet unresolved question. The scientific endeavor continues, driven by the hope that compounds like creatine, with their established safety profiles and unique biological functions, might one day offer new avenues of relief for millions grappling with the debilitating effects of depression. The path forward demands scientific rigor, careful observation, and a commitment to understanding the intricate interplay between physical health and mental well-being.
